AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN EBITDA Margin

EBITDA as a percentage of revenue.

AstraZeneca PLCNYSE: AZN

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 36.9%

EBITDA Margin was 36.9% in Q3 FY2026, up 2.5 pp from a year earlier. On a trailing-twelve-month basis it was 34.4%, up 3.4 pp year over year. Over 3 fiscal years it widened by 13.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 47.7% for the fiscal year ending Dec 2026, up from 33.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
36.9%+3.4 pp QoQ
Last fiscal yearDec 2025
33.8%+5.2 pp YoY
LTMSep 2026
34.4%+3.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.5 pp+13.3 pp+10.7 pp
1 year+5.2 pp+14.0 pp+8.8 pp
3 years+13.3 pp+16.0 pp+2.8 pp
5 years+19.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
33.8%
Year-over-year change
+5.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AZN compares with its peers on the latest reported figures

  • AZN's LTM Sep 2026 EBITDA Margin of 34.4% is the 6th highest of the 10 companies compared; the peer median is 36.6%.
  • Its year-over-year change of +3.4 pp is the 3rd highest of 10, against a peer median of -0.5 pp.
  • Over three fiscal years its change of +13.3 pp compares with a peer median of +7.3 pp.
AZN Competitors Peer median
EBITDA Margin for AZN and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202654.9% -0.5 pp+7.3 pp
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202634.2% +2.6 pp-10.0 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
Peer median (excluding AZN) 36.6%-0.5 pp+7.3 pp

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.